

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version 12.0      Revision Date: 11/13/2025      SDS Number: 20462-00026      Date of last issue: 05/09/2025  
Date of first issue: 10/09/2014

### SECTION 1. IDENTIFICATION

Product name : Raltegravir Pediatric Granules Formulation

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

**GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

#### Hazards for the product as supplied

Serious eye damage : Category 1

Reproductive toxicity : Category 2

#### Other hazards

Contact with dust can cause mechanical irritation or drying of the skin.

#### Hazards associated with a change in physical form:

Conditions	Hazards
If small particles are generated during further processing, handling or by other means.	May form combustible dust concentrations in air.

#### GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H318 Causes serious eye damage.  
H361d Suspected of damaging the unborn child.

Supplemental Hazard Statements : Corrosive to the respiratory tract.

Precautionary Statements : **Prevention:**

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version 12.0      Revision Date: 11/13/2025      SDS Number: 20462-00026      Date of last issue: 05/09/2025  
Date of first issue: 10/09/2014

P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P261 Avoid breathing dust.  
P271 Use only outdoors or in a well-ventilated area.  
P280 Wear protective gloves, protective clothing, eye protection and face protection.

### Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a doctor if you feel unwell.  
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER.  
P308 + P313 IF exposed or concerned: Get medical attention.

### Storage:

P405 Store locked up.

### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Raltegravir	871038-72-1*	>= 10 - <= 30	TSC
Cellulose	9004-34-6*	>= 10 - <= 30	TSC
Polyethylene glycol	25322-68-3*	>= 1 - <= 5	TSC
Magnesium stearate	557-04-0*	>= 0.5 - <= 1.5	TSC

\* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

## SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

		of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Causes serious eye damage. May cause respiratory irritation. Suspected of damaging the unborn child. Corrosive to the respiratory tract. Contact with dust can cause mechanical irritation or drying of the skin.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Nitrogen oxides (NO <sub>x</sub> ) Fluorine compounds Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Surround spill with absorbents and place a damp covering over the area to minimize entry of the material into the air.  
Add excess liquid to allow the material to enter into solution.  
Soak up with inert absorbent material.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Avoid breathing dust.  
Do not swallow.  
Do not get in eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers.  
Minimize dust generation and accumulation.  
Keep container closed when not in use.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version 12.0      Revision Date: 11/13/2025      SDS Number: 20462-00026      Date of last issue: 05/09/2025  
Date of first issue: 10/09/2014

Conditions for safe storage : Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.  
Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Keep in a cool, well-ventilated place.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

inert or nuisance dust	50 Million particles per cubic foot Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	15 mg/m <sup>3</sup> Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
	5 mg/m <sup>3</sup> Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3
	15 Million particles per cubic foot Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3
Dust, nuisance dust and particulates	10 mg/m <sup>3</sup> Value type (Form of exposure): PEL (Total dust) Basis: CAL PEL
	5 mg/m <sup>3</sup> Value type (Form of exposure): PEL (respirable dust fraction) Basis: CAL PEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Raltegravir	871038-72-1	TWA	1000 (µg/m <sup>3</sup> ) (OEB 1)	Internal
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable)	5 mg/m <sup>3</sup>	NIOSH REL
		TWA (total)	10 mg/m <sup>3</sup>	NIOSH REL
		TWA (total dust)	15 mg/m <sup>3</sup>	OSHA Z-1
		TWA (respirable fraction)	5 mg/m <sup>3</sup>	OSHA Z-1

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version 12.0      Revision Date: 11/13/2025      SDS Number: 20462-00026      Date of last issue: 05/09/2025  
Date of first issue: 10/09/2014

Polyethylene glycol	25322-68-3	TWA (aero-sol)	10 mg/m <sup>3</sup>	US WEEL
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

### Personal protective equipment

**Respiratory protection** : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**  
**Material** : Chemical-resistant gloves

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.  
**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance** : powder

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version 12.0	Revision Date: 11/13/2025	SDS Number: 20462-00026	Date of last issue: 05/09/2025 Date of first issue: 10/09/2014
-----------------	------------------------------	----------------------------	---

---

Color	:	off-white
Odor	:	odorless
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

Particle size : No data available

### SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Calculation method

#### Components:

##### **Raltegravir:**

Acute oral toxicity : LD50 (Mouse, male and female): > 2,000 mg/kg  
Acute inhalation toxicity : Assessment: Not corrosive to the respiratory tract.

##### **Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

##### **Polyethylene glycol:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423



# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

	Remarks: Based on data from similar materials
Acute dermal toxicity	: LD50 (Rat): > 2,000 mg/kg
	Remarks: Based on data from similar materials

### Magnesium stearate:

Acute oral toxicity	: LD50 (Rat): > 2,000 mg/kg
	Method: OECD Test Guideline 423
	Assessment: The substance or mixture has no acute oral toxicity
	Remarks: Based on data from similar materials
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg
	Remarks: Based on data from similar materials

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Raltegravir:

Species	: Rabbit
Result	: No skin irritation

#### Polyethylene glycol:

Species	: Rabbit
Method	: OECD Test Guideline 404
Result	: No skin irritation
Remarks	: Based on data from similar materials

#### Magnesium stearate:

Species	: Rabbit
Result	: No skin irritation
Remarks	: Based on data from similar materials

### Serious eye damage/eye irritation

Causes serious eye damage.

### Components:

#### Raltegravir:

Species	: Bovine cornea
Result	: Severe irritation

#### Polyethylene glycol:

Species	: Rabbit
Result	: No eye irritation
Method	: OECD Test Guideline 405
Remarks	: Based on data from similar materials

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

### Magnesium stearate:

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

#### Respiratory sensitization

Not classified based on available information.

### Components:

#### Raltegravir:

Test Type	:	Local lymph node assay (LLNA)
Species	:	Mouse
Result	:	negative

#### Polyethylene glycol:

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Result	:	negative
Remarks	:	Based on data from similar materials

#### Magnesium stearate:

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative
Remarks	:	Based on data from similar materials

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Raltegravir:

Genotoxicity in vitro	:	Test Type: reverse mutation assay Result: negative
		Test Type: Alkaline elution assay Test system: rat hepatocytes Result: negative
		Test Type: Chromosomal aberration Method: OECD Test Guideline 473 Result: negative

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

Genotoxicity in vivo	: Test Type: In vivo micronucleus test Species: Mouse Result: negative  Test Type: Chromosomal aberration Method: OECD Test Guideline 475 Result: negative
----------------------	--

### Cellulose:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

### Polyethylene glycol:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials
-----------------------	---

### Magnesium stearate:

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials  Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials  Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials
-----------------------	---

### Carcinogenicity

Not classified based on available information.

### Components:

#### Raltegravir:

Species	: Mouse, male and female
Exposure time	: 104 weeks
Result	: negative

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

### Cellulose:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 72 weeks
Result	: negative

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### Reproductive toxicity

Suspected of damaging the unborn child.

### Components:

#### Raltegravir:

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, male and female Application Route: Oral General Toxicity Parent: NOAEL: 600 mg/kg body weight Result: negative
Effects on fetal development	: Species: Rat Application Route: Oral General Toxicity Maternal: NOAEL: $\geq$ 600 mg/kg body weight Teratogenicity: LOAEL F1: 300 mg/kg body weight Symptoms: Skeletal malformations. Result: positive  Species: Rabbit General Toxicity Maternal: NOAEL: $\geq$ 1,000 mg/kg body weight Teratogenicity: NOAEL: $\geq$ 1,000 mg/kg body weight Result: negative
Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments.

### Cellulose:

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on fetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

II

### Magnesium stearate:

Effects on fertility	:	Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative Remarks: Based on data from similar materials
Effects on fetal development	:	Test Type: Embryo-fetal development Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials

### STOT-single exposure

May cause respiratory irritation.  
Corrosive to the respiratory tract.

### Components:

#### Raltegravir:

Routes of exposure	:	Inhalation
Target Organs	:	Respiratory Tract
Assessment	:	May cause respiratory irritation.

### STOT-repeated exposure

Not classified based on available information.

### Repeated dose toxicity

### Components:

#### Raltegravir:

Species	:	Dog
NOAEL	:	90 mg/kg
Application Route	:	Oral
Exposure time	:	371 d
Symptoms	:	Vomiting

Species	:	Rat
NOAEL	:	30 mg/kg
LOAEL	:	120 mg/kg
Application Route	:	Oral
Exposure time	:	189 d
Target Organs	:	Stomach

Species	:	Mouse
NOAEL	:	50 mg/kg
LOAEL	:	500 mg/kg
Application Route	:	Oral
Exposure time	:	14 Weeks

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

Target Organs : Stomach

Species : Rat  
NOAEL : 50 mg/kg  
LOAEL : 200 mg/kg  
Application Route : Oral  
Exposure time : 8 Weeks  
Target Organs : Stomach

### Cellulose:

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

### Magnesium stearate:

Species : Rat  
NOAEL :  $> 100$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

### Components:

#### Raltegravir:

Ingestion : Symptoms: Nausea, Diarrhea, Headache, Fever, Rash, Skin irritation

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

### Components:

#### Raltegravir:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)):  $> 100$  mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
  
LC50 (Cyprinodon variegatus (sheepshead minnow)):  $> 100$  mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
  
Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)):  $> 100$  mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): 66 mg/l Exposure time: 96 h Method: OECD Test Guideline 201  NOEC (Pseudokirchneriella subcapitata (green algae)): 3.8 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 9.3 mg/l Exposure time: 33 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 9.5 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	: EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209  NOEC: 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

### Cellulose:

Toxicity to fish	: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	--

### Polyethylene glycol:

Toxicity to fish	: LC50 (Poecilia reticulata (guppy)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
------------------	---

### Magnesium stearate:

Toxicity to fish	: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

Toxicity to algae/aquatic plants	: EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility.  NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	: EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

### Persistence and degradability

#### Components:

##### **Raltegravir:**

Biodegradability	: Result: rapidly degradable Biodegradation: 50 % Exposure time: 9 d Method: OECD Test Guideline 302B
Stability in water	: Hydrolysis: < 10 % (5 d) Method: OECD Test Guideline 111

##### **Cellulose:**

Biodegradability	: Result: Readily biodegradable.
------------------	----------------------------------

##### **Polyethylene glycol:**

Biodegradability	: Result: rapidly degradable Remarks: Based on data from similar materials
------------------	---

##### **Magnesium stearate:**

Biodegradability	: Result: Not biodegradable Remarks: Based on data from similar materials
------------------	--

### Bioaccumulative potential

#### Components:

##### **Raltegravir:**

Partition coefficient: n-octanol/water	: log Pow: -0.328
--	-------------------



# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

### Polyethylene glycol:

Partition coefficient: n-octanol/water : log Pow: < 3

### Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

### Mobility in soil

No data available

### Other adverse effects

No data available

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to IMO instruments

Not applicable for product as supplied.

### Domestic regulation

#### 49 CFR

Not regulated as a dangerous good

### Special precautions for user

Not applicable

## SECTION 15. REGULATORY INFORMATION

### CERCLA Reportable Quantity

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Reproductive toxicity  
Serious eye damage or eye irritation

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

### US State Regulations

#### Pennsylvania Right To Know

D-Mannitol	69-65-8
Raltegravir	871038-72-1
Cellulose	9004-34-6
Polyvinyl pyrrolidone	9003-39-8
Ammonium hydroxide	1336-21-6

#### California List of Hazardous Substances

Polyvinyl pyrrolidone	9003-39-8
-----------------------	-----------

#### California Permissible Exposure Limits for Chemical Contaminants

Cellulose	9004-34-6
Magnesium stearate	557-04-0

#### The ingredients of this product are reported in the following inventories:

AICS	: not determined
CA. DSL	: not determined
IECSC	: not determined

## SECTION 16. OTHER INFORMATION

### Further information

# SAFETY DATA SHEET


according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

### NFPA 704:



### HMIS® IV:

HEALTH	*	3
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

### Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
CAL PEL	: California permissible exposure limits for chemical contaminants (Title 8, Article 107)
NIOSH REL	: USA. NIOSH Recommended Exposure Limits
OSHA Z-1	: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
OSHA Z-3	: USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
US WEEL	: USA. Workplace Environmental Exposure Levels (WEEL)
ACGIH / TWA	: 8-hour, time-weighted average
CAL PEL / PEL	: Permissible exposure limit
NIOSH REL / TWA	: Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	: 8-hour time weighted average
OSHA Z-3 / TWA	: 8-hour time weighted average
US WEEL / TWA	: 8-hr TWA

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemi-

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Raltegravir Pediatric Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05/09/2025
12.0	11/13/2025	20462-00026	Date of first issue: 10/09/2014

cals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 11/13/2025

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8